Kornimate/medical-research-clean huggingface dataset:
assess the effect of treating periodontal disease on cardiovascular function in young adults

Conditions: Periodontal Disease; Atherosclerosis

Summary: we propose to examine a population of native americans who have had little or no dental care, and to determine if periodontal disease is associated with early signs of vascular dysfunction or systemic inflammation. we then propose to treat the periodontitis and re-evaluate vascular function. we will determine if gingivitis or mild/moderate periodontitis is associated with detectable vascular dysfunction. microbial metagenomics will be correlated with vascular function.


Eligibility criteria:
inclusion criteria: * american indian/alaskan natives seeking health care at the indian health council, inc. * males and females aged 21-40 years. exclusion criteria: * recent (within 6 months) periodontal treatment * history of high blood pressure or existing heart disease * xerostomia * currently receiving treatment for cancer * currently taking anti-inflammatory medications (except h2 blockers, statins, or medications that can affect periodontal status * immunosuppressed due to medication or hiv infection, or presence of active infection such as hepatitis or tuberculosis * fewer than 20 teeth in functional dentition, excluding third molars, or other gross oral pathology

Keywords: periodontal disease atherosclerosis oral pathogens native americans inflammatory cytokines microbial metagenomics
long-term efficacy and safety of hms5552 in t2dm subjects

Conditions: Diabetes Mellitus, Type 2

Summary: this study evaluates the efficacy and safety and population pk of hms5552 as monotherapy in adult type 2 diabetic subjects, there will be 2 groups in the first 24 weeks, one group will receive hms5552 , while the other group will receive placebo ; after 24 weeks, all subjects will receive hms5552 for 28 weeks.

this study is a phase iii study in subjects with t2dm. as designed, the study will start with a 4-week, single-blind, placebo run-in period based on diet and exercise interventions for screening eligible subjects. the eligible subjects are randomly assigned to hms5552 75mg bid group or placebo bid group with ratio 2:1 to receive a 24-week double-blind treatment. then all subjects receive 28-week open-label treatment of hms5552 75mg bid . after 52-week treatment, all investigational drugs should be discontinued, followed by 1 week for safety evaluation.

Eligibility criteria:
inclusion criteria: 1. male or female, aged 18\~75 years old 2. naive t2dm 3.7.5% ≤ hba1c ≤ 11.0% at screening 4.18.5 kg/m2 \< bmi \< 35.0 kg/m2 at screening; exclusion criteria: 1. t1dm 2. fasting c-peptide \<1.0 ng/ml (0.33 nmol/l) at screening 3. medical history of severe hypoglycemia, diabetic ketoacidosis, diabetes lactic acidosis or hyperosmotic nonketotic diabetic coma, severe cardio-cerebrovascular,unstable or rapidly progressive kidney disease, active liver diseases,diagnosed mental disease,etc

Keywords: gka t2dm hms5552 monotherapy
prolactin hormone in rheumatoid arthritis patients with periodontitis

Conditions: Rheumatoid Arthritis; Periodontitis

Summary: in this study we will assess the presence of prolactin hormone in the gingival crevicular fluid , and synovial fluid of patient with rheumatoid arthritis and periodontitis


Eligibility criteria:
inclusion criteria: * for first group patients with active rheumatoid arthritis with periodontitis. * second group , patients with periodontitis and otherwise systemically healthy * third group, systemically and periodontallly healthy subjects exclusion criteria: * smokers, * pregnant or lactating females * patients taking medications the affects levels of prolactin hormone. * no periodontal treatment in the past six months
comparing two types of swabs in collecting cell samples for anal pap tests and human papillomavirus tests in men who have sex with men

Conditions: Anal Cancer; Nonneoplastic Condition; Precancerous Condition

Summary: rationale: doctors use a swab to collect cell samples when testing for anal cancer and human papillomavirus. it is not yet known which type of swab is more effective in collecting cell samples for anal pap tests and human papillomavirus tests in men who have sex with men. purpose: this clinical trial is comparing two types of swabs in collecting cell samples for anal pap tests and human papillomavirus tests in men who have sex with men.

objectives: * to determine whether the anal cytology screening outcome derived from specimens collected by a flocked nylon swab are equivalent to those derived from dacron swab specimens in men who have sex with men. * to determine whether the number and type-specific identification for human papillomavirus derived from specimens collected by a flocked nylon swab are equivalent to those derived from dacron swab specimens. outline: dry sterile dacron swabs and flocked nylon swabs are used to collect intra-anal cytology specimens for anal pap testing and human papillomavirus typing. participants undergo a digital rectal examination and high-resolution anoscopy. if lesions are identified, an anal biopsy is performed for histological examination.

Eligibility criteria:
inclusion criteria: * hiv-infected or -uninfected adult men who have sex with men * concurrent enrollment in the multicenter aids cohort study required exclusion criteria: * history of anal perforation or other medical contraindications

Keywords: human papilloma virus infection anal cancer hiv infection
acetoacetate and acetate metabolism in patients with chronic kidney failure.(reno-tep)

Conditions: Kidney Failure, Chronic

Summary: the objective of this study is to nake a comparison between 11c-acetate and 11c-acetoacetate kidney uptake in chronic kidney failure patients.

chronic kidney failure patients will be ask to perform two positron emission tomography scan during the same day. one, with a 11c-acetate tracer and the other with 11c-acetoacetate. the results will allow to determine the difference between the two tracers and will ultimately be compared with precedent results of healthy controls.

Eligibility criteria:
inclusion criteria: * bmi between 18.5 and 40 * kidney failure if gfr betweem 30 and 60 ml/min/1.73m2 * stable medication for at least 4 weeks exclusion criteria: 1. receive cytotoxic therapy for primary or secondary kidney disease within 6 months prior to enrollment 2. organ transplant history 3. class iv congestive heart failure (new york heart association) 4. myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrollment 5. coronary revascularization (percutaneous coronary intervention or arterial bypass) or valve repair/replacement within 12 weeks of enrollment or is scheduled to undergo one of these procedures within 4 weeks of enrollment 6. any condition outside the realm of renal and cardiovascular disease, such as, but not limited to, malignancy, with a life expectancy of less than 2 years in the clinical judgment of the investigator 7. active malignancy requiring treatment at visit 1 (except successfully treated basal or squamous cell carcinoma). 8. hepatic impairment (aspartate transaminase or alanine transaminase \>3x upper limit of normal; or total bilirubin \>2x upper limit of normal at time of enrollment 9. pregnancy or lactation 10. adherence to a ketogenic diet, consumption of ketogenic products or supplements or intermittent fasting or other diet or supplements that may significantly increase ketones in the past two months. 11. daily alcohol consumption \>2 servings per day 12. participation in other interventional research projects concurrently or participation in other pet research projects in the last year, which exceeds the recommended limits 13. inability to lie still in supine position; 14. medical fluid restriction limiting fluid intake for the procedure

Keywords: ketone acetoacetate acetate
study of folfiri chemotherapy with or without sunitinib in patients with metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the purpose of the study is to evaluate the safety and efficacy of folfiri (irinotecan, leucovorin and 5 fluorouracil) chemotherapy when combined with sunitinib or folfiri chemotherapy without adding sunitinib as the first line treatment of patients with metastatic colorectal cancer.

on june 25, 2009, the independent data monitoring committee (dmc) reviewed the progress of study a6181122. the dmc determined study a6181122 had met pre-specified futility criteria and was unlikely to meet its primary endpoint to demonstrate a statistically significant improvement in progression-free survival (pfs) in patients treated with sunitinib plus folfiri versus placebo plus folfiri. no new safety findings were noted. pfizer notified clinical trial investigators involved in the study and regulatory agencies of these findings. patients receiving benefit on treatment as determined by the investigator may remain on study.

Eligibility criteria:
inclusion criteria: * confirmed (histologically or cytologically) colorectal adenocarcinoma with metastatic disease. * not received previous therapy for metastatic colorectal disease but for whom folfiri treatment is clinically indicated. * adequate organ function defined by blood test. exclusion criteria: * history of another primary cancer in the last 3 years. * previous full field radiotherapy within the last 4 weeks or limited field radiotherapy within 2 weeks of enrolling into the study. or previous radiation treatment of more that 30% of the bone marrow. * history of presence of brain metastasis, spinal cord compression carcinomatous meningitis or leptomeningeal disease.

Keywords: colorectal neoplasms
safety, tolerability, pk and efficacy of azd1152 in patients with relapsed acute myeloid leukemia

Conditions: Myeloid Leukemia

Summary: the purpose of this study is to assess safety and tolerability of multiple ascending doses of azd1152 and to assess effect of azd1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.


Eligibility criteria:
inclusion criteria: * relapsed or refractory aml for which no standard therapies are anticipated to result in durable remission * newly diagnosed aml who are not considered suitable for other treatments. exclusion criteria: * previous myeloablative therapy allogeneic bone marrow or stem cell transplantation, radiotherapy or chemotherapy within 4 weeks of first dose. * participation in any other trial with an investigational product within the previous 30 days * other active malignancy.

Keywords: aml phase i/ii azd1152 acute myeloid leukaemia
differential rehabilitative treatment for pelvic floor in sportswoman

Conditions: Pelvic Floor Disorder

Summary: in this study at least 24 sportswoman (18-50 years old) will be recruited a randomized in two groups which will be differently treated for the following 8 weeks. one group will be treated with kegel approach and the other one with de gasquet apporach. before and after the treatment they will fill in a battery of falidated questionnaire in order to evaluate the improvement at pelvic floor level, quality of life and psychological distress.

in this study at least 24 sportswoman (18-50 years old) with pelvic floow symptos (18-50 years old) will be recruited a randomized in two groups which will be differently treated for the following 8 weeks. they should havo no children, other relevant systemic disorders and assume no drugs. they should practice sports by at least one year. one group will be treated with kegel approach and the other one with de gasquet apporach. before and after the treatment they will fill in a battery of falidated questionnaire in order to evaluate the improvement at pelvic floor level, quality of life and psychological distress. in partiqular they fill in: * pelvic floor distress inventory (pfdi-20) * incontinence severity index (isi) * quality of life questionnaire (sf-36) * king's health questionnaire (khq) * intestinal related symptoms questionnaire (iciq-b) * depression anxiety stress scale (dass-21)

Eligibility criteria:
inclusion criteria: * practicing sports by at least one year exclusion criteria: * no systemic disorders * no drugs assumption * no children

Keywords: pelvic floor rehabilitation
tislelizumab monotherapy versus salvage chemotherapy for relapsed/refractory classical hodgkin lymphoma

Conditions: Classical Hodgkin Lymphoma

Summary: the primary objective of this study is to evaluate the efficacy of tislelizumab in participants with relapsed or refractory classical hodgkin lymphoma (chl), as measured by progression-free survival (pfs) as assessed by investigator


Eligibility criteria:
key inclusion criteria: 1. histologically confirmed chl.must have relapsed or refractory ( chl and 1. has failed to achieve a response or progressed after autologous hematopoietic stem cell transplant (asct). or 2. has received at least two prior lines of systemic chemotherapies for chl and is not an asct candidate. 2. must have measurable disease 3. eastern cooperative oncology group (ecog) performance status of 0 or 1. 4. must have adequate organ functions. 5. prior chemotherapy, radiotherapy, immunotherapy or investigational therapy used to control cancer including locoregional treatment must have been completed ≥ 4 weeks before the first dose of study drug, and all treatment-related adverse events are stable and have either returned to baseline or grade 0/1 key exclusion criteria: 1. nodular lymphocyte-predominant hodgkin lymphoma or gray zone lymphoma. known central nervous system (cns) lymphoma. 2. prior allogeneic hematopoietic stem cell transplant. asct or chimeric antigen receptor t-cell immunotherapy (car-t) within 100 days of first dose of study drug. 3. prior therapies targeting pd-1 or pd-l1. 4. prior malignancy within the past 3 years except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast. 5. participant with active autoimmune disease or history of autoimmune disease with high risk of recurrence. 6. serious acute or chronic infection requiring systemic therapy. 7. known human immunodeficiency virus (hiv), or serologic status reflecting active hepatitis b virus (hbv) or hepatitis c virus (hcv) infection. note: other protocol defined inclusion/exclusion criteria may apply.
jit: effect of pain on dt in tmd

Conditions: Temporomandibular Disorder (TMD)

Summary: individuals with chronic temporomandibular disorder (tmd) pain are at increased risk for alcohol-related consequences compared to those without pain, and growing evidence suggests pain is a potent motivator for alcohol use in many individuals. however, few systematic examinations of modifiable and non-modifiable risk factors, including orofacial pain status, have been conducted. this project addresses this gap in knowledge by determining the effect of pain on drinking topography in heavy drinkers with and without chronic tmd pain in both the laboratory and daily life.


Eligibility criteria:
inclusion criteria: * participants in this study must be 21 years to 65 years of age and provide a driver's license or other state-issued id. * participants must also be sufficiently fluent in english to provide informed consent and understand questionnaires and instructions for laboratory procedures. * participants in this study must report regular drinking exceeding niaaa guidelines for (≥ 2 (men) or ≥ 1 (women) drinks per day on average) over the past six months, as well as drinking on ≥ 2 days/week. * meet diagnostic criteria for temporomandibular disorders (dc/tmd) for myalgia (masticatory muscle pain), arthralgia (tmj pain), or a combination (schiffman et al., 2014) (tmd group only). * own a smartphone with internet access. * use of prescription medications will be allowed, provided they do not contraindicate alcohol use. exclusion criteria: * use of opioid analgesics within the past month; * current major depression; * history of any psychotic disorder; * under-controlled hypertension or diabetes (as reflected by self-report); neurological disease (e.g., multiple sclerosis, epilepsy, amyotrophic lateral sclerosis, parkinson's disease); * serious medical illness (e.g., hepatitis, hiv/aids); * impaired cognitive function; * history of substance use disorder (including nicotine/tobacco); * alcohol naïve * alcohol use disorder, or currently attempting to quit or cut down on using alcohol * positive pregnancy test * breastfeeding or intending to become pregnant * loss of sensation in the lower leg * inability to complete study tasks due to weakness, immobilization, or loss of limbs * chronic pain (control group only) * a urine-based drug screen for tetrahydrocannabinol, cocaine, benzodiazepines, morphine, and methamphetamine (innovacon, inc., san diego, ca) will be performed. participants testing positive for any substance will be discontinued. * medications that contraindicate alcohol use

Keywords: alcohol temporomandibular disorder (tmd) chronic pain
testing supportgroove: a novel mhealth intervention for couples coping with spinal cord injury

Conditions: Spinal Cord Injuries; Relationship, Marital

Summary: the purpose of this study is to test the preliminary effects of an 8-week mobile application-based program (supportgroove) developed for persons with spinal cord injury and their romantic partners.

eligible couples who provide informed consent will be enrolled in the study and will be randomized to either immediately start the 8-week supportgroove program or be waitlisted for 8-weeks before starting the program. while actively participating in the program, couples will use the app to engage in daily "quests" (positive psychology-based activities to be completed on their own or as a couple). both partners in the participating couple complete self-report assessments at baseline (0 weeks), 8 weeks, 16 weeks, and 28 weeks.

Eligibility criteria:
inclusion criteria: * cohabitating romantic couples where one partner has sustained a spinal cord injury at least 3 months prior to enrolling in the study * be able to read and understand printed english instructions * have a smartphone, tablet, or personal computer with internet access exclusion criteria: * the partner has a spinal cord injury or other major neurological condition * either partner is unable to read and understand printed english instructions * either partner does not consent to participate in the study

Keywords: spinal cord injuries couple relationship resilience
median nerve function during phalen's test

Conditions: Carpal Tunnel Syndrome

Summary: this study will use electromyography and nerve conduction studies to evaluate median nerve function during the phalen's wrist flexion test in different wrist positions.

the phalen's test is commonly used to assess carpal tunnel syndrome. however, it is unclear which wrist position during this test best isolates median nerve function. this study will measure thenar muscle activation and median nerve conduction in 30 healthy participants performing the phalen's test. different wrist flexion angles will be evaluated to determine which position optimally targets the median nerve. results may enhance utilization of the phalen's test in clinical practice and research.

Eligibility criteria:
inclusion criteria: * healthy adults aged 18-45 years * no history of hand/wrist disorders exclusion criteria: * contraindications to emg or ncv * neurological or muscular disorders
postoperative prognosis management service based mhealth for gastric cancer patients

Conditions: Gastric Cancer

Summary: recently, the use of mobile health is increasing for the purpose of managing prognosis such as recurrence, survival and quality of life by using a wearable smart band together with a smartphone application. in the era of the 4th revolution, mobile health for the purpose of comprehensive prognosis for cancer patients is becoming a very good tool. as a result of applying a mobile application for health management (nutrition, health education, exercise, etc.) to 203 gastric cancer or colon cancer patients undergoing chemotherapy in the previous study, gastric cancer patients are most interested in health-related education and information. as such, it was possible to confirm the clinical significance of short-term and temporary health care through mobile applications and smart bands during the treatment process for gastric cancer patients, but the study was insufficient to generalize the number of subjects. therefore, until now, the results of a multicenter randomized-control study have not been found after long-term application as a supportive tool from immediately after surgery (before treatment) to during the treatment process. therefore, in gastric cancer patients who need prognosis management after surgery, we will investigate the effect of mobile application with smart band which has a modular structure reflecting the treatment method and treatment process after surgery. this study targets patients who underwent gastric cancer surgery, an intervention group (app+iot device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band for 12 months. control group was provided general education through the hospital brochure. evaluation will be conducted 2-3days after surgery (before discharge), and at 1, 3, 6, and 12 months after surgery.


Eligibility criteria:
inclusion criteria: * ajcc stage i-iii who has undergone radical gastric cancer surgery (chemotherapy, radiation therapy is irrelevant) * patients aged 19 to 75 years old * those who can use prognosis management applications and can perform regular follow-up inspections outpatients * patients carrying android or ios smartphones * patients who voluntarily decide to participate and give written consent after hearing detailed explanations about this study exclusion criteria: * those who have difficulty using gastric cancer applications (exercise performance, diet management, etc.) due to severe underlying diseases, neuromusculoskeletal diseases, cognitive, and visual impairments